Autophagy is associated with chemoresistance in neuroblastoma by unknown
RESEARCH ARTICLE Open Access
Autophagy is associated with
chemoresistance in neuroblastoma
Assila Belounis1,2, Carine Nyalendo3, Roxane Le Gall1, Tina V. Imbriglio1, Mohamed Mahma1, Pierre Teira4,
Mona Beaunoyer5, Sonia Cournoyer1, Elie Haddad1, Gilles Vassal6 and Hervé Sartelet1,2,7*
Abstract
Background: Neuroblastoma (NB) is a frequent pediatric tumor characterized by a poor prognosis where a majority
of tumors progress despite intensive multimodality treatments. Autophagy, a self-degradative process in cells, could
be induced by chemotherapy and be associated with chemoresistance. The aim of this study was to determine
whether: 1) autophagy is present in NB, 2) chemotherapy modified its levels, and 3) its inhibition decreased
chemoresistance.
Methods: Immunohistochemical stainings were performed on samples from 184 NB patients in order to verify the
expression of LC3B, a specific marker for autophagy, and Beclin 1, a positive regulator of autophagy. In addition, we
performed an in vitro study with six NB cell lines and six drugs (vincristine, doxorubicin, cisplatin temozolomide,
LY294002 and syrolimus). Inhibition of autophagy was performed using ATG5 knockdown cells or
hydroxychloroquine (HCQ). Cell survival was measured using the MTT cell proliferation assay. Autophagy was
detected by monodansylcadaverine, confocal microscopy and Western blot. In vivo study with tumor xenografts in
NSG mice was performed.
Results: Our results have indicated that autophagy was present at low levels in NB and was not a prognostic
factor, while Beclin 1 was highly expressed in children with poor NB prognosis. However, autophagy levels
increased after chemotherapy in vitro and in vivo. Tumor progression was significantly decreased in mice treated
with a combination of HCQ and vincristine.
Conclusions: Taken together, autophagy is present in NB, induced by chemotherapy and associated with
chemoresistance, which is significantly reduced by its inhibition. Therefore, targeting autophagy represents a very
attractive approach to develop new therapeutic strategies in NB.
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Background
Neuroblastoma (NB) is the most common and deadly ex-
tracranial solid tumor in children [1, 2]. Survival of children
older than one year of age with advanced NB is poor (only
34%), despite aggressive treatments [3, 4]. High-dose
chemotherapy with autologous hematopoietic stem cell
transplantation significantly improves the prognosis of
metastatic NB [5, 6], but this treatment carries with it a
high risk of adverse effects [4]. Poor global survival and
resistance to high-dose chemotherapy indicate that NB is
specifically associated with chemoresistance [7].
Autophagy is a ubiquitous self-degradation process that
involves the degradation and recycling of cellular cytoplas-
mic constituents through the lysosomal pathway. Damaged
or misfolded proteins or organelles are first sequestered in
double-membrane vesicles, known as autophagosomes,
before fusing with lysosomes, where their contents are de-
graded by lysosomal proteases [8–10]. Autophagy is a com-
plex and multistep process involving the autophagy-related
proteins (ATG) [8]. ATG5 is a protein involved in the early
stages of autophagosome formation and plays an essential
role in the maturation of autophagosomes [11], with assist-
ance from LC3 [8]. Low levels of autophagic activity are
* Correspondence: hsartelet@chu-grenoble.fr
1Research centre of the Sainte Justine university hospital, Montreal, QC,
Canada
2Department of pathology and cellular biology, Université de Montréal,
Montreal, QC, Canada
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Belounis et al. BMC Cancer  (2016) 16:891 
DOI 10.1186/s12885-016-2906-9
commonly observed under normal conditions, presumably
preserving normal cellular homeostasis [12, 13]. Prolonged
autophagy may result in type 2 (autophagic) programmed
cell death [12, 14]. The activation of autophagy is measured
by the ratio between LC3II on the autophagosome mem-
brane and LC3I in the cytoplasm which can be detected by
Western-blot [15] or by immunohistochemistry [16]. Beclin
1 is also a marker and a positive regulator of autophagy.
The regulation of autophagy by the PI3K/AKT pathway
is very complex. Recently, an AKT inhibitor was reported
to induce autophagy with a radiosensitizing effect [17]. Au-
tophagy is regulated by both class I and III PI3K pathways
[18, 19]. mTOR serves as a metabolic sensor that coordi-
nates cross-talk between nutrient availability and autophagy
[19]. On the other hand, class III PI3K in conjunction with
Beclin 1 positively regulates autophagy [18, 19].
In cancer, autophagy plays a dual role by either activating
cell death and inhibiting tumor progression or promoting
cell survival [20]. In the early stages of carcinogenesis,
autophagy acts as a primary tumor suppressor and inhibits
tumor progression [21]. However, autophagy can also
confer tumor cells the ability to resist to ionizing radiation
[22] as well as to chemotherapy [23].
The observation of increased cell survival associated with
higher autophagy activity following therapy has led to the
development of strategies combining autophagy inhibitors
to current anticancer treatments. In this context, chloro-
quine (CQ) or its derivate hydroxychloroquine (HCQ), sen-
sitizes tumor cells to anticancer therapies. Indeed, CQ and
HCQ block the processing and maturation of autophagy
vacuoles (autophagolysosomes) by inhibiting lysosomal ac-
tivity [23]. Some data suggest that autophagy inhibition and
autophagosome accumulation both contribute to the
accelerated cell death induced by HCQ [23].
The aim of the present study is to demonstrate the
presence of autophagy in NB, its activation by chemo-
therapy and its correlation with chemoresistance.
Methods
Study design and patients
Study cases were selected upon the following inclusion
criteria; 1) a diagnosis of NB had been made between
July 1988 and March 2008, 2) human subject research
(tissue samples) was approved by the Research Ethics
Board of the Sainte-Justine University Health Center.
Written consent has been obtained from patient
guardians, and 3) adequate specimen material has been
collected for study purposes. 184 patients with NB were
included in our study. The patients were treated and
followed up at Sainte-Justine University Health Center
(Montreal, Canada). Thirty-one out of 184 total NB
cases were identified from routine provincial (Quebec,
Canada) mass screening efforts. Tumors were classified
according to the International Neuroblastoma Staging
System (INSS) [24]. Treatment was assigned according
to the risk group on the basis of the patient’s age at time
of diagnosis, the INSS stage, the histoprognosis, the
ploidy and MYCN amplification status (v-myc avian
myelocytomatosis viral oncogene neuroblastoma derived
homolog). With formalin-fixed and paraffin-embedded
samples, a tissue microarray (TMA) was constructed
using four representative NB tumor tissue cylinders with
a 0.6 mm diameter. TMA blocks contained not only 184
primary tumors but also 47 paired metastases (42 lymph
nodes and 5 hepatic metastases). Among the 184
tumors, 19 tumors were tested by Western blot, proteins
coming from the lysate of frozen samples.
Immunohistochemistry
Immunohistochemistry was performed on the sections of
the TMA blocks or of tumors developed in the mouse
model. The Ultraview Universal DAB detection kit
(Ventana, Ventana medical system, Tuscon, AR) was used.
Antibodies against phospho-AKT (1/100, S473-r, Santa
Cruz biotechnology, CA), phospho-mTOR (1/100, 49 F9,
Cell Signaling, CA), LC3B (1/1000, ab51520 abcam,
Cambridge UK) or Beclin 1 (1/250, ab55878 abcam) were
applied for 30 min. DAB was used as a chromogen and
hematoxylin as a counterstain. Normal mouse or rabbit
IgG at the same concentration as the primary antibody
were used as negative control and synaptophysin (1/100,
Polyclonal, SP11, Thermofisher Scientific) as positive
control (Additional file 1: Figure S1). Two investigators
blinded for clinical data independently evaluated
immunostaining in samples containing more than 100 NB
cells. Immunostaining scores were established by a semi-
quantitative optical analysis assessing the percentage of
positive cells in each sample: 0 = all cells negative, 1 + = 1
to 25%, 2 + = 26 to 50%, 3 + = 51 to 75% and 4+ more than
75% of positive tumoral cells.
TUNEL
On the sections of TMA, a terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL)
assay (In situ cell death detection kit, POD (Roche)) was
used to identify double-stranded DNA fragmentation, char-
acteristic of DNA degradation due to apoptosis. Briefly, tis-
sue slides were deparaffinized. The slides were then treated
with 0.1% of Triton X-100 (Sigma, X-100). The slides were
then incubated with terminal deoxynucleotidyl transferase
followed by peroxidase-conjugated anti-digoxigenin anti-
body. Finally, the slides were stained with DAB. Methyl
green was performed as the counter-stain. Slides were
scanned using a customized, computer-controlled micro-
scope (Axio Imager M1; Zeiss, Oberkochen, Germany).
The percentage of positive neuroblasts for TUNEL was also
calculated by dividing the number of stained nuclei by the
total numbers of neuroblasts and multiplying by 100.
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Cell lines
Six NB cell lines were studied: SK-N-DZ (ATCC, Manassas,
VA), SK-N-SH (ATCC), SK-N-FI (ATCC), IGR-N91 and
IGR-NB8 cells from Gustave Roussy Institute (Villejuif,
France), and NB-10 (St. Jude Children’s Hospital, Memphis,
TN). MYCN amplification is present in NB-10, SK-N-DZ
and IGR-N91 cells. The cells were cultured in Dulbecco’s
modified Eagle medium (DMEM), 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin at 37 °C in a 5% CO2
atmosphere.
Knockdown of ATG5 expression by lentivirus-delivered
shRNA
TRC Lentiviral Human ATG5 and eGFP shRNA vectors
(ATG5: accession #NM_004849, eGFP: accession #
RHS4459) were purchased from Open Biosystems,
Rockford, IL. Lentiviral vectors were produced using HEK
293 T cells by PEG (polythylenimine linear, Polysciences
inc) transfection of ATG5 or eGFP shRNA plasmid
together with the third-generation packaging plasmids
pMDL, pRev and pV-SVG (Open Biosystems). To generate
human ATG5-knockdown cells, IGR-N91 cells were
transduced with lentivirus expressing shATG5 or sheGFP
for control. Transduced cells were cultured in fresh
medium for 2 days before selection for stable expression of
the shRNA by growing in culture media containing
puromycin (5 μg/mL) for at least 2 weeks.
GFP-LC3 transfection and confocal microscopy
The cell line IGR-N91 was transfected with GFP-LC3
(Millipore’s LentiBrite TM GFP-LC3 lentiviral Biosensor)
for monitoring autophagosome formation. IGR-N91 cells
were seeded at 4 × 105/well into eight-well chamber slides
(Thermo Scientific, Rochester, NY) to achieve 70%
confluence. After 24 h, the cells were transfected with
lentivirus containing a version of GFP-LC3 at 37 °C, 5%
CO2 for 24 h. At 48 h post-transfection, the medium was
changed to DMEM, 1% fetal bovine serum (FBS) and 1%
penicillin-streptomycin, the cells were washed three times
with PBS and visualized with the Ultraview Vox Confocal
Imaging System (Perkin Elmer). The autophagosome
volume in transfected cells was evaluated with Imaris 7.7.2
software (Oxford Instruments Company).
Cell proliferation assay
Cell viability was determined by the MTT test. Cells
were plated in a 96-well culture plate at a density of
5x103/well over night. The cells were treated with
Table 1 Patients clinical data
Variable LC3B Beclin-1
No (%) No % Mean
Intensity
p No % Mean
Intensity
p
All patients 184 148 80 0.83 153 83 1.03
Age
Median (Range), months 26 (0–151)
<365 days 88 (48) 73 83 0.92 70 80 0.83
≥365 days 96 (52) 74 77 0.75 ns 84 87.5 1.25 <0.01
Stage
1 53 (29) 47 88 0.6 ns 48 90 1.30 ns
2 35 (19) 25 71 0.64 27 77 0.8
3 23 (12) 21 91 0.94 20 86 1.14
4 58 (32) 52 89 1.12 47 81 0.97
4S 15 (8) 11 73 0.34 0.02 11 73 0.72 ns
MYCN status
Amplified 14 (10) 13 87 0.81 11 73 0.87
Non Amplified 127 (90) 103 81 0.50 ns 105 82 0.43 ns
Unknown 43
Type of NB
Standard 149 (81) 133 89 0.96 126 84 1.19
Mass screening 35 (19) 29 82 0.8 ns 27 77 0.46 <0.001
Type of samples
Primary tumors 184 148 80 0.83 153 83 1.03
Metastases 47 41 87 0.78 ns 37 79 0.69 <0.01
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various conditions for 24 h then proliferation was mea-
sured by the (3-[4,5dimethyl-2-thiazolyl]-2,5-diphenyl-
2H-tetrazolium bromide) MTT cell proliferation assay
(Cell Titer 96 Non-Radioactive Cell proliferation Assay,
Promega) according to manufacturer’s instructions.
Absorbance was measured at 570 nm using the Spectra
Max 190 microplate spectrophotometer (Molecular
Devices, Sunnyvale, CA). Assays were performed in
triplicate. Relative cell viability (percent of control) was
calculated using the equation: (mean OD of treated
cells/mean OD of control cells) × 100. For each time
point, the treated cells were compared with control cells
that had been treated with vehicle only.
Monodansylcadaverine (MDC) test
To correlate cell survival with the presence of autopha-
gic vacuoles, cells were incubated with the autofluores-
cent agent monodansylcadaverine (MDC) at 0.05 mM in
PBS (Sigma) for 10 min at 37 °C. MDC has been
reported to specifically label autophagic vacuoles [25].
MDC was then replaced with 200 μl of PBS and finally
replaced by 100 μl of Tris-Triton (Tris 10 mM pH 8.0,
0.1% Triton X-100). Fluorescence was measured with
EnVision 2104 multilabel reader (Perkin Elmer) with an
emission filter of 525 nm at 380 nm.
Cell treatments
The MTT and MDC tests were performed on cell lines
with or without transfection of ATG5 shRNA vector and
treated with different concentrations of drugs for 24 h at
37 °C: temozolomide (Schering Plough inc, 0.1–1000 μM),
vincristine (Mayne Pharma USA inc, Paramus NJ,
1–10000 nM), doxorubicin (Pfizer Inc Kirkland, Canada,
0.005–50 μM) and cisplatin (Mayne Pharma USA inc,
Paramus NJ; 0.015–150 μg/ml), LY294002, specific
inhibitor of AKT (Calbiochem Darmstadt, Germany,
0.05–500 μM) and rapamycin, specific inhibitor of mTOR
(Pfizer Inc Kirkland, Canada 0.1–1000 nM). Finally, cells
were treated with varying concentrations of cisplatin
(0.15–75 μg/mL) and doxorubicin (0.005–5 μg/mL) in the
presence and absence of HCQ (30 μM) for 48 h. The com-
pound concentrations resulting in 50% inhibition of cell
viability (IC50) were determined using GraphPad Prism 6
software. The cell line IGR-N91 transfected with GFP-LC3
were treated with vincristine (1 μM), with HCQ (30 μM)
or with the association of the two drugs and then analyzed
with confocal microscopy for 7 h.
Western Blot
Protein extracts were prepared from frozen tumor
tissues of 19 patients and cultured cell lines. Cell lysis
buffer with protease inhibitor cocktail (10 mM Tris–HCl
pH 7.4, 150 nM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X-100, 0.5% NP-40, 1 mM sodium orthovanadate,
1 mM sodium fluoride) was added to each sample. Equal
amounts of protein (20 μg) from cell lysates were solubi-
lized in Laemmli sample buffer, boiled for 5 min, sepa-
rated by SDS-PAGE, transferred onto polyvinylidene
difluoride (PVDF) membranes, blocked 1 h at room
temperature with TBS buffer (20 mM Tris–HCl, pH 7.4,
150 mM NaCl) containing 3% bovine serum albumin,
and incubated with primary antibody overnight at 4 °C.
Immunoreactive bands were revealed following 1 h
incubation with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse antibodies, and the signals
were visualized with an enhanced chemiluminescence
(ECL) detection system (PerkinElmer, Waltham, MA).
The primary antibodies used for this study were: β-actin
(13E5; diluted 1:5000, Cell Signaling, Danvers, MA),
mouse polyclonal anti-human PARP-1 (Ab-2; 1:600;
Calbiochem, Billerica, MA), rabbit polyclonal anti-
human Beclin 1 (1/1000, ab55878 abcam, Cambridge
UK), rabbit polyclonal anti-human SQSTM1/p62, LC3B
and ATG5, rabbit monoclonal anti-human Cleaved
Caspase-3 (Asp175), mTOR (7C10), phospho-mTOR
(Ser2448, D9C2), Akt and phospho-Akt (Ser473), (all
diluted 1:1000, Cell Signaling, Danvers, MA). A densi-
tometry analysis with the Kodak ID 3.6 software was
used to calculate the relative expression of Cleaved
Caspase-3 and the ratio between LC3B-II and LC3B-I.
Animal experiments
NOD/LtSz-scid/IL-2Rgamma null mice (NSG) were pur-
chased from Jackson Laboratory (Bar Harbor, ME, USA).
Animal experiments were approved by the CEEA26
Ethics Committee (approval number: 2013–099) and
carried-out under the conditions established by the
European Community (Directive 2010/63/UE). All mice
were housed in ventilated cages under standard condi-
tions of controlled temperature and humidity, and
(See figure on previous page.)
Fig. 1 Evaluation of the level and the regulation of autophagy in NB and its correlation with apoptosis. A Autophagy was evaluated in TMA
sections from NB tumor samples by immunohistochemistry using antibodies anti-LC3B (A.a,b) or anti-Beclin 1 (A.c). The expression levels of
pmTOR (A.e) and pAKT (A.f), two autophagy-regulating proteins, were also studied on the same samples. Apoptosis was tested by TUNEL (A.d).
Scale bars: 100 μm. B Immunoblotting analysis was performed on protein lysates from different frozen matched tumor samples with antibodies
against either LC3B or Beclin 1 for autophagy and against cleaved caspase-3 for apoptosis. C The expression of LC3II and TUNEL positivity were
semi-quantified according to the stage of tumors. D The ratio LC3II/LC3I and cleaved caspase-3 expression were evaluated by densitometry using
tumor samples
Belounis et al. BMC Cancer  (2016) 16:891 Page 5 of 14
Fig. 2 (See legend on next page.)
Belounis et al. BMC Cancer  (2016) 16:891 Page 6 of 14
exposed to a 12-hourly light/dark cycle. They were
provided with standard diet and water ad libitum. First,
NSG were established in 6 to 8 week-old mice by sub-
cutaneous injection of 5 × 106 IGR-N91 in the left flank.
Mice were monitored twice a week for tumor growth.
Clinical monitoring of mice (weight, vital signs, behavior
and abdominal palpation) were carried out once a week.
When the palpable tumor reached 100 mm3 (measured
with calipers), 6 mice/group received a dose of vincris-
tine (0.4 mg/kg) [26] or HCQ (60 mg/kg) or an associ-
ation of vincristine and HCQ at the same concentration
was injected daily for 9 consecutive days. Six control
mice received (100 μL) of saline solution per day. Mice
were euthanized at the onset of clinical signs or when
bearing tumors of 1000 mm3 or at the end of the
treatment.
Secondly, five millions of SK-N-DZ cells (100 μL) were
injected s.c. in the left flank. Mice were treated with
vincristine (0.4 mg/kg) or cisplatin (Mayne Pharma,
Canada) i.p. at 8 mg/kg for 4 days [27, 28]. Mice
receiving PBS at the same time were used as a negative
control. In all in vivo experiments, mice were euthanized
10 days after the end of treatment or when tumor size
reached 1000 mm3. Tumors were collected and
immunohistochemistry with LC3B antibody was
performed.
Statistical analysis
Association tests were performed with the use of Fisher’s
exact test. Spearman correlation values (rho) were used
to compare the expression between LC3-II and pmTOR,
pAKT and between Beclin 1 and pAKT. Statistical ana-
lyses were performed using GraphPad Prism 6 software.




Clinicopathological characteristics of the 184 patients
and tumors are detailed in (Table 1). These patients had
a median follow-up period of 67 months (range
newborn-174 months) and a median age at the time of
diagnosis to be 26 months (range newborn-151 months).
Autophagy and neuroblastoma
The analysis of LC3 immunostaining clearly showed two
types of positivity: uniform cytoplasmic staining, corre-
sponding to LC3I (Fig. 1Aa) and a punctate cytoplasmic
LC3-staining pattern specific to LC3II and therefore to
autophagy (Fig. 1Ab). Furthermore, autophagy was
frequent in NB (80% of the tumors) but with a very low
intensity (mean intensity 0.83). These data were con-
firmed by Western blot analysis where LC3II expression
was found in 12 out of 19 tumors (63%) (Fig. 1B). The
cytoplasmic expression of Beclin 1 was also expressed in
a majority of NB (83%) but with a low intensity (mean
intensity 1.03) (Fig. 1Ac, Table 1). These data were
confirmed by Western blot analysis showing Beclin 1
expression in 17 out of 19 tumors (90%) (Fig. 1B).
The LC3II expression was significantly higher in Stage
4 (mean intensity 1.12) than in Stage 4S (mean intensity
0.34) (Table 1, p = 0.02), confirmed by Western blot,
where LC3II was undetectable in specimen from Stage
4S patients. Interestingly, the level of apoptosis detected
by TUNEL (Fig. 1Ad) and by cleavage of caspase-3 was
inversely correlated with autophagy, particularly in
Stages 4 and 4S (Fig. 1C and D). However, expression
levels of Beclin 1 were significantly higher in patients
older than one year at diagnosis compared to younger
patients (p < 0.001) (Table 1), in primary tumors than in
metastasis (p < 0.01) and in standard NBs than in tumors
coming from mass screening (p < 0.001), demonstrating
that Beclin 1 is highly expressed in NB with poor
prognosis. Among the major proteins present in the
AKT pathway, there was a significant negative correl-
ation between LC3II and pmTOR (Fig. 1Ae) (rho =
−0.22, p < 0.01) as well as pAKT (rho = −0.22, p < 0.01)
and between Beclin 1 and pAKT (Fig. 1Af) (rho = −0.13,
p < 0.01), suggesting that autophagy is activated through
AKT pathway inhibition.
Chemotherapy induces autophagy in neuroblastoma cells
The formation of autophagosomes revealed by MDC
indicates a significant increase of autophagy following
treatment with increasing concentrations of cisplatin,
vincristine and doxorubicin (Fig. 2a). Temozolomide
didn’t induce high levels of autophagy even at high con-
centrations. AKT pathway inhibitors, such as LY294002
(See figure on previous page.)
Fig. 2 Chemotherapy induces autophagy in vitro and in vivo. The effect of chemotherapeutic agents on the autophagy of NB cell lines and tissues was
analyzed. a NB-10 cells were treated with increasing concentrations of temozolomide, rapamycin, cisplatin, vincristine, doxorubicin or LY294002 for 24 h
followed by MTT and MDC assays to measure cell viability and autophagy levels, respectively. Results are expressed as percentage of the corresponding
control and represent mean ± SEM of 3 independent experiments (***: P< 0.001). b Cell viability and MDC specific autophagy were measured after IC50
treatment of different NB cell lines with chemotherapeutic agents. Results are expressed as percentage of the corresponding control and represent mean
± SEM of 3 independent experiments (***: P< 0.001). c Immunobloting analyses were performed on protein lysates from SK-N-SH and IGR-N91 cells treated
with 0.1 to 10 μM of vincristine. Anti PARP-1, anti-LC3B, anti-p62, anti-mTOR, anti-pmTOR antibodies were used. β-actin was used as a loading control.
d Tumor xenografts developed from SK-N-DZ or IGR-N91 cells were treated with cisplatin or vincristine. Slides were immunostained with anti-LC3B
antibody. Scale bars: 100 μm
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and rapamycin, were the most efficient, resulting in high
autophagy levels (Fig. 2a). Following an IC50 concentra-
tion treatment, autophagy increased with all drugs in the
four cell lines, independently to MYCN amplification
(Fig. 2b). SK-N-SH and IGR-N91 cells incubated with
vincristine for 24 h showed a moderate conversion of
LC3I to LC3II suggesting that cells undergo apoptosis.
In addition, p62 expression decreased when cells were
treated with this drug demonstrating the presence of
autophagy. This result was also confirmed by confocal
analysis where assessment of LC3 showed a constant in-
crease in cytoplasmic autophagosome formation in cells
treated with vincristine (refer to Fig. 4c). This increased
of autophagy was correlated with an increase of acti-
vated mTOR expression but only for the low concentra-
tion of vincristine (Fig. 2c). The induction of autophagy
by chemotherapy was also found in in vivo experiments
with strong LC3II positivity in tumors of NSG mice
injected with SK-N-DZ and treated with cisplatin or
IGR-N91 treated with vincristine (Fig. 2d).
Inhibition of autophagy sensitizes NB cells to
chemotherapy
Transfection efficiency with lentivirus-based short hair-
pin RNA for ATG5 knockdown (ATG5kd) was confirmed
by Western blot and by MDC (Fig. 3a and b). ATG5kd
cells were significantly more sensitive to vincristine,
doxorubicin or cisplatin than sheGFP cells (Fig. 3c), sug-
gesting that autophagy contributes to chemoresistance
in NB.
Treatment with HCQ induced an inhibition of the late
stage of autophagy which was shown by an increase of
the LC3II/LC3I ratio but no decrease of p62 in Western
blot (Fig. 4a), as well as an accumulation of autophago-
some detected by confocal microscopy (Fig. 4c and
Additional file 2: Figure S2) and an increase of MDC
positivity (Fig. 4d). The inhibition of autophagy was not
correlated with increase of cell death (Fig. 4a and b).
HCQ treatment does not modify the expression of
pmTOR but decreases phosphorylated AKT levels at
high concentrations (Fig. 4a).
The MTT test showed that cells treated with a com-
bination of HCQ 30 μM and vincristine (0.001–100 μM)
or doxorubicin (0.001–100 μM) were significantly more
sensitive to chemotherapy than cells treated with vincris-
tine or doxorubicin alone (Fig. 4e and Additional file 3:
Figure S3A), confirming that HCQ increases sensitivity
to chemotherapy. The MDC test also showed a
dose-dependent increase of autophagosome numbers
after treatment, enhanced by addition of HCQ, consistent
with a late inhibition of autophagy (Fig. 4f and Additional
file 3: Figure S3B).
Autophagy inhibition decreases tumor progression in
vivo
To further investigate the effect of autophagy inhibition
on tumor progression, we compared tumor development
in mice treated or not with HCQ, vincristine or a com-
bination of HCQ and vincristine. At the end of the treat-
ment, the tumor volume was significantly lower in mice
treated with HCQ and HCQ combined to vincristine
than in control (p < 0.05 and p < 0.01 respectively). The
association of HCQ and vincristine is significantly more
efficient than vincristine alone (p < 0.05). Interestingly,
HCQ used alone have a similar efficiency as vincristine
alone (Fig. 5).
On another side, tumors were developed in 11/12 mice
injected with sheGFP cells versus only 3/12 in mice
injected with ATG5kd cells (Additional file 4: Figure S4).
Discussion
Despite aggressive multimodal therapy, NB patients still
have a poor prognosis, which is partially explained by
chemoresistance of the tumor cells. Furthermore, it has
been reported that autophagy is a potential mechanism
that promotes tumor cell survival and confers chemore-
sistance [29]. In our study, we observed that autophagy
is present at basal levels to maintain homeostasis. LC3
expression was not correlated to any clinicopathological
data. However, autophagy was higher in Stage 4 tumors
than 4S while apoptosis was lower in Stage 4 tumors
than stage 4S, which could explain the aggressive
properties of Stage 4 tumors compared to 4S. Beclin 1 is
a factor of poor prognosis as it is highly expressed in tu-
mors from NB patients older than one year old. In other
cancers, such as human hypopharyngeal squamous cell
carcinoma (HSCC), expression of Beclin 1 and LC3II
correlates with poor prognosis [30]. Additionally, other
studies showed that autophagy predicts resistance to
chemotherapy and survival in melanoma [31]. We also
observed a negative correlation between LC3II and
pAKT as well as pmTOR and between Beclin 1 and
(See figure on previous page.)
Fig. 3 Inhibition of autophagy sensitizes NB cells to chemotherapy. IGR-N91 cells were transduced with ATG5-shRNA lentivirus to knockdown ATG5 gene
expression and thereby inhibit autophagy or with eGFP-shRNA, used as a control. a Protein immunoblotting using anti-ATG5 and anti-LC3B antibodies was
performed to demonstrate ATG5 gene knockdown and LC3 expression on IGR-N91-transduced cells or not (WT). β-actin was used as a loading control.
b A MDC test for autophagy was performed on ATG5kd and control cells after treatment with increasing concentrations of vincristine. c Cell viability of
ATG5kd and control cells was measured with a MTT assay following treatment with increasing concentrations of vincristine, doxorubicin or cisplatin. Results
are expressed as percentage of corresponding control and represent mean ± SEM of 4 independent experiments (*: P< 0.05, ***: P< 0.001)
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pAKT, suggesting that autophagy activation occurs after
inhibition of the AKT pathway since the inhibition of
mTOR activates autophagy.
To determine whether autophagy is activated after
chemotherapy treatment, three chemotherapeutic
agents, used clinically for NB treatment, were studied:
vincristine, doxorubicin and cisplatin. Our data demon-
strate that the activation of autophagy by cisplatin and
vincristine is dose-dependent. This is also observed with
doxorubicin except in one cell line (SK-N-FI). These
data were confirmed by in vivo study that show the acti-
vation of autophagy in NB tumors from mice receiving
the cisplatin or vincristine treatment compared to non-
treated tumors. In other cancers, doxorubicin is known
as an inducer of the autophagosome formation in
papillary thyroid cancer [32], whereas cisplatin induced
autophagy in esophageal squamous cell carcinoma cells
[33]. The MYCN gene amplification in several cell lines
used in our study could change the state of autophagy
indeed several studies have showed that overexpression
of CMYC strongly induces autophagy in rat 3Y1 fibro-
blasts [33, 34]. Our data indicate that NB cell lines with
amplified MYCN (SK-N-DZ, IGR-N91) didn’t show
increased autophagy comparing to other cell lines with
non-amplified MYCN. Temozolomide has been de-
scribed as an inducer of autophagy [35]. In the present
study, temozolomide doesn’t induce a dose-dependent
increase of autophagy, detectable by MDC and by
Western blot. Differently, the present study showed that
LY294002 was a dose dependent activator of autophagy.
This drug increases autophagy by inhibiting PI3K I, an
element of the PI3K/AKT/mTOR inhibitory pathway to
autophagy [36]. Rapamycin induces autophagy by
inhibiting mTOR [37]. In the present study, an increase
in autophagy detected by MDC was associated with
treatment by rapamycin in the four studied NB cell lines.
It has been described that in the presence of rapamycin,
the dephosphorylation of many proteins activates the
transcription of ATG8 and ATG14 genes, known to be
associated with autophagy [13].
Beclin 1 has many cell functions, such as inducing
autophagosome formation and acting as a tumor sup-
pressor [38]. It is a mediator of various cellular cascades,
including autophagy, apoptosis and cell differentiation
[39]. The association of certain genes of the Bcl-2 family
with Beclin 1 inhibits the autophagic function by
(See figure on previous page.)
Fig. 4 HCQ sensitizes NB cells to chemotherapy by inhibition of autophagy. a IGR-N91 and SK-N-SH cells were treated with 15 to 60 μM of HCQ and
analyzed for LC3B, p62, mTOR, p-mTOR, AKT, pAKT, Beclin 1 protein expression by immunoblotting. β-actin was used as a loading control. b Cell viability
of SK-N-DZ, IGR-N91 and IGR-NB8 was measured using an MTT assay pre and post HCQ treatment (30 μM). c Confocal microscopy analysis was done on
transfected IGR-N91 cells with GFP-LC3 not treated or treated 7 h with HCQ 30 μM, vincristine 1 μM or the combination of the two drugs. d Autophagy
in SK-N-DZ, IGR-N91 and IGR-NB8 cells was measured by an MDC assay pre and post HCQ treatment (30 μM). e SK-N-DZ cell viability was measured after
vincristine or doxorubicin treatment combined or not with HCQ (30 μM). f The autophagic activity of SK-N-DZ cells was measured using a MDC agent
after treatment with vincristine or doxorubicin, combined or not with HCQ (30 μM). Results are expressed as percentage of corresponding control and
represent mean ± SEM of 4 independent experiments (*: P< 0.05, **: P< 0.01, ***: P< 0.001)
Fig. 5 Effect of autophagy inhibition by HCQ on tumors in vivo. Six NSG mice of each group received a s.c injection of 5x106 IGR-N91 cells. When tumors
reached 100 mm3, mice were administered vincristine (0.4 mg/kg/day), HCQ (60 mg/kg), an association of vincristine and HCQ or vehicle (saline) for 9 days.
The tumor size of the four groups of mice was compared during this period
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limiting its partnering with a class III PI3K and activates
its apoptotic function instead [40]. It is the positive
regulation of Beclin 1 that induces the autophagic and
differentiation cascades [39]. Also, Beclin 1 loses its au-
tophagic abilities and induces apoptosis when there is an
increased activity of caspase-9 [41]. This caspase has the
property of cleaving Beclin 1 and creating a C-terminal
fragment promoting pro-apoptotic activity [41]. Accord-
ing to some studies, doxorubicin activates caspase-9 and
positively regulates the expression of Beclin 1 [41]. Con-
sequently, this particular NB drug induces apoptosis.
Collectively, our data demonstrate that autophagy is acti-
vated in response to chemotherapy in NB cells but has not
answered if this autophagy is an autophagy-mediated cell
death or autophagy-mediated cell survival (chemoresis-
tance). We investigated the effect of combining chemo-
therapy with autophagy inhibition. In the early stages of
carcinogenesis, autophagy acts as a primary tumor suppres-
sor and inhibits tumor progression [21]. However, once
tumor is established, autophagy tend to be a protective
mechanism used by tumors cells to overcome chemother-
apy and other metabolic stress. We used HCQ to target the
late stages of autophagy by blocking the fusion of autopha-
gosomes with lysosomes [42]. Interestingly, mice treated
with HCQ alone have decreased tumors volume compared
to mice treated with vincristine. This results support some
clinical trials that use HCQ alone to treat patients with
pancreatic cancer, breast cancer, renal cell carcinoma or
chronic lymphocytic leukemia [23, 43]. In the present study,
HCQ was used at non-toxic concentrations that trigger
autophagy inhibition. Our data demonstrated that mice
treated with a combination of vincristine and HCQ develop
tumors with a significantly less extend than mice treated
with vincristine alone. These data demonstrate, for the first
time, that inhibition of autophagy using HCQ sensitizes NB
cells to classical chemotherapy supporting the idea that au-
tophagy acts as a cytoprotective mechanism [44] and its in-
hibition may promote apoptosis in cancer cells [45]. Several
studies and clinical trials have investigated autophagy
inhibition using different pharmacological agents, usually in
combination with chemotherapy, radiotherapy or other tar-
geted anti-cancer therapies [46]. Some data demonstrated a
significant increase in long-term survival when the treat-
ment includes CQ [47]. Reports from clinical trials indicate
that when CQ was added to conventional therapy, im-
provement of mid-term survival for glioblastoma multiform
patients was seen [48]. Taken together, these results
confirm that autophagy promotes chemoresistance and its
inhibition sensitizes NB cells to chemotherapy.
Conclusions
Our study demonstrates that autophagy is present in NB
tumors at a basal level and it is activated after chemo-
therapeutic that confers chemoresistance. The use of
HCQ sensitizes cells to the conventional chemotherapy
in NB treatment. Therefore, we propose that HCQ could
be used as an adjuvant therapy in clinical trials to
enhance the efficacy of chemotherapy in NB patients.
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Additional file 1: Figure S1. Control for immunogistochemistry.
Normal mouse or rabbit IgG at the same concentration as the primary
antibody were used as negative control (NC) and synaptophysin (1/100,
Polyclonal, SP11, Thermofisher Scientific) as positive control (PC).
(PDF 379 kb)
Additional file 2: Figure S2. GFP-LC3 transfection and confocal
microscopy. The cell line IGR-N91 transfected with GFP-LC3 were not
treated (a), treated with vincristine alone (1 μM) (b), with HCQ (30 μM)
alone (c) or with the association of the two drugs (d) and then analyzed
with confocal microscopy for 7 h. Treatment with HCQ induced an
inhibition of the late stage of autophagy which was shown an
accumulation of autophagosome. (PDF 789 kb)
Additional file 3: Figure S3. HCQ sensitizes NB cells to chemotherapy
by inhibition of autophagy. A. N91-IGR or NB8-IGR cell viability was
measured after vincristine or doxorubicin treatment combined or not to
HCQ 30 µM. Results are expressed as percentage of corresponding control
and represent mean ± SEM of 4 independent experiments. B. Autophagic
activity of N91-IGR or NB8-IGR was measured using MDC agent after
increasing concentration of vincristine or doxorubicin treatment combined
or not to HCQ 30 µM. Fluorescence was quantified by spectrophotometer.
(*: P < 0.05), (**: P < 0.01), (***: P < 0.001). (PDF 215 kb)
Additional file 4: Figure S4. Effect of ATG5 knockdown xenografts on
tumor growth. (11/12) NSG Mice developed xenograft tumor from s.c
injection of 5.106 sheGFP cells and only (3/12) from shATG5 cells (Table
A). When tumor reached 200 mm3, mice were administered vincristine
(0.4 mg/kg/day) or vehicle (saline) for 5 days. Progression of tumor
volume was followed in each group. Each data point represents the
mean 6 ± SE tumor volume for sheGFP cells and 1 or 2 for shAtg5 cells.
At day 6, Tumors size from shATG5 cells were reduced compared with
tumors from eGFP (B). Also, tumors from shATG5 cells were more
sensitive to vincristine comparing to control cells. Immunohistochemistry
was performed on the sections of tumors developed in the mouse
model. with LC3 antibody and showed a high expression of LC3 II in
control cells and a very low in cells ATG5 knockdown as well as treated
(b, d) or not treated (a, c) (C). (PDF 259 kb)
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